172015-99-5

Basic information

• Product Name: Cyclopropanecarboxamide,N,N-diethyl-2-(hydroxymethyl)-1-phenyl-,(1S,2R)-
• Synonyms: Cyclopropanecarboxamide,N,N-diethyl-2-(hydroxymethyl)-1-phenyl-,(1S,2R)-;(1S,2R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropane-carboxamide
• CAS NO: 172015-99-5
• Molecular Weight: 247.337
• Mol File: 172015-99-5.mol

Chemical Properties

• CAS DataBase Reference: Cyclopropanecarboxamide,N,N-diethyl-2-(hydroxymethyl)-1-phenyl-,(1S,2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxamide,N,N-diethyl-2-(hydroxymethyl)-1-phenyl-,(1S,2R)-(172015-99-5)
• EPA Substance Registry System: Cyclopropanecarboxamide,N,N-diethyl-2-(hydroxymethyl)-1-phenyl-,(1S,2R)-(172015-99-5)

Safety Data

• Hazardous Substances Data: 172015-99-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopropanecarboxamide, N,N-diethyl-2-(hydroxymethyl)-1-phenyl-,(1S,2R)is used as a pharmaceutical compound for its potential therapeutic applications. Its unique structure allows it to interact with biological systems, making it a promising candidate for the development of new drugs and therapies.
Used in Medicinal Chemistry Research:
Cyclopropanecarboxamide,N,N-diethyl-2-(hydroxymethyl)-1-phenyl-,(1S,2R)is used as a research tool in medicinal chemistry to explore its interactions with biological systems and understand its potential therapeutic effects. Its unique cyclopropane ring and amide functional group provide a foundation for studying the compound's properties and mechanisms of action.
Used in Drug Discovery:
Cyclopropanecarboxamide, N,N-diethyl-2-(hydroxymethyl)-1-phenyl-,(1S,2R)is utilized in drug discovery processes to identify and develop new pharmaceutical agents. Its chiral nature and unique structural features make it an interesting target for the design and synthesis of novel drugs with potential therapeutic benefits.

Upstream product

• 140-29-4 phenylacetonitrile 
• 63106-93-4 (1S,5R)-1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one 
• 34992-80-8 sodium di(ethyl)amine 
• 109-89-7 diethylamine 
• 63106-93-4 1-phenyl-3-oxa-bicyclo[3.1.0]hexan-2-one 
• 816-43-3 lithium diethylamide 

Downstream Products

• 172016-00-1 (1S,2R)-2-Formyl-1-phenyl-cyclopropanecarboxylic acid diethylamide 
• 174848-98-7 (1S,2R)-2-(azidomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide 
• 1001017-62-4 (1S,2R)-2-(bromomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide 
• 96847-54-0 (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide 
• 1237261-65-2 (1S,2R)-2-((1,3-dioxoisoindolin-2-yl)methyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide-cyclopropanecarboxamide 
• 101152-94-7 (1S,2R)-milnacipran hydrochloride 
• 923037-67-6 C₂₂H₂₇NO₄S 
• 1237261-60-7 (1S,2R)-2-(chloromethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide 
• 174747-08-1 (1S,2R)-2-((S)-1-Hydroxy-ethyl)-1-phenyl-cyclopropanecarboxylic acid methyl ester 
• 172016-04-5 (1S,2R)-1-phenyl-2-<(R)-1-azidopropyl>-N,N-diethylcyclopropanecarboxamide 
• 171889-16-0 (1S,2R)-1-phenyl-2-<(S)-1-azidopropyl>-N,N-diethylcyclopropanecarboxamide 
• 172016-03-4 (1S,2R)-1-phenyl-2-<(R)-1-azidoethyl>-N,N-diethylcyclopropanecarboxamide 
• 171889-14-8 (1S,2R)-2-((S)-1-Hydroxy-propyl)-1-phenyl-cyclopropanecarboxylic acid diethylamide 
• 172016-02-3 (1S,2R)-1-phenyl-2-<(R)-1-hydroxypropyl>-N,N-diethylcyclopropanecarboxamide 

Relevant articles and documents

Preparation method of milnacipra hydrochloride intermediate

The invention provides a preparation method of an intermediate hydrochloride intermediate. Belong to chemical medicine preparation technical field. To the preparation method, the compound having the structure of the formula (II) is added into the methanol

Preparation of leveminacipran hydrochloride

The invention discloses a novel preparation method for synthesizing leveminacipran hydrochloride, and relates to a compound represented by a formula A. According to the invention, each step of reaction is simple in operation and mild in condition, use of

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

PROCESS FOR THE PREPARATION OF (1S,2R)-MILNACIPRAN

The invention relates to a process for the preparation of Levomilnacipran, a compound useful in the treatment of depression, comprising the following steps: a) directly converting the enantiomerically enriched form of alcohol (D) into the enantiomerically enriched form of the phthalimido derivative (C) by treatment with phthalimide in the presence of a trialkyl or triarylphosphine and of a dialkyl azodicarboxylate, formula (I) wherein the amount of phthalimide is comprised between 1 and 1.3 equivalents with respect to the molar amount of alcohol (D) used, and the amounts of both the phosphine and the azodicarboxylate are comprised, independently from each other, between 1 and 1.5 equivalents with respect to the molar amount of alcohol (D) used; b) deblocking the enantiomerically enriched form of the phthalimido derivative (C) to obtain Levomilnacipran, formula (II).

Preparation method of levomilnacipran hydrochloride

The invention provides a preparation method of levomilnacipran hydrochloride. According to the preparation method, a mixed liquid is obtained through a mixed reaction of a compound adopting the structure shown in the formula (II) and alkali; then acid is

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.

PROCESS FOR PREPARING LEVOMILNACIPRAN HCL

The invention relates to one-pot process for preparing (1S,2R)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-aminomethylcyclopropane of formula (I) comprising the step of reacting (1S,2R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropanecarboxamide successively with the following reactants 1) triethyl orthoformate and methanesulfonic acid or triethylamine and methanesulfonyl chloride, 2) a phthalimidating agent, 3) aqueous EtNH2, wherein the reaction is carried out in toluene. In another aspect the invention concerns a process for preparing (1S,2R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropanecarboxamide trough a step of crystallization of (1S,5R)-1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one.

AN IMPROVED PROCESS FOR THE PREPARATION OF 1-ARYL 2-AMINOMETHYL CYCLOPROPANE CARBOXYAMIDE (Z) DERIVATIVES, THEIR ISOMERS AND SALTS

The present invention relates to an improved and one-pot process for the preparation of 1-Aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers of formula (I) or its pharmaceutically acceptable salt thereof wherein R1 and R2 are represents independently selected from the group consisting of hydrogen, lower alkyl, lower aryl, and lower-alkylaryl, which aryl or alkylaryl group is optionally substituted by a halogen atom.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of neurological conditions may he formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may he used to treatment: of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multipie sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.

Enantioselective synthesis of levomilnacipran

A novel approach for the asymmetric synthesis of the active (1S,2R)-enantiomer of the antidepressant milnacipran is reported. The two stereogenic centers borne by the cyclopropane ring were sequentially installed starting from phenylacetic acid.